ALKS:NASDAQ
Alkermes Plc
$46.27
arrow_upward
+0.19%(+0.090) 1D
Nov 20, 9:30:37 AM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
High
$46.42
Mkt. cap
7.78B
Avg. vol.
1.71M
Volume
7.74K
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
High
$46.42
Mkt. cap
7.78B
Avg. vol.
1.71M
Volume
7.74K
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
News stories
From web sources and news partners
Reuters
·
23 minutes ago
SocGen sees S&P 500 ending 2027 at 8,500 on AI, earnings support
Traders Union
·
35 minutes ago
Ryan Detrick: S&P 500 posts six-day losing streak, longest since April 2024
Bloomberg.com
·
54 minutes ago
S&P 500 Faces Technical Make-or-Break Moment Below 7,200 Line
Barron's
·
2 hours ago
S&P 500 Futures Decline in Premarket Trading; Lennar, Louisiana-Pacific Lag
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitealkermes.com